Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 210

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 210
---
, with Longevity surviving the Business Combination as a wholly owned subsidiary
of FutureTech. Below are the pre-Closing and the post-Closing entity structure charts that illustrate the effect of the Business Combination.

Pre-closing Structure

| 101 |

Post-closing Structure

Closing of the Transactions

The Closing is
expected to take place three business days following the satisfaction or waiver of the conditions described below under the subsection
entitled “— Conditions to Closing,” unless FutureTech or Longevity agree in writing to another time or unless
the Merger Agreement is terminated. The Business Combination is expected to be consummated promptly after the approval by FutureTech’s
public stockholders at the Special Meeting of such stockholders described in this proxy statement/prospectus.

Merger Consideration

The aggregate
consideration (the “Merger Consideration”) to be paid to the holders of Longevity common stock, par value $0.0001 per share
(the “Longevity Common Stock”), at the Closing will consist of a number of shares of common stock, par value $0.0001 (“FutureTech
Common Stock”) equal to (a) (i) $100,000,000 minus (ii) the value of each outstanding option (whether vested or unvested) to purchase
Longevity Common Stock that is converted into a new option in accordance with the Merger Agreement, divided by (b) $10.00.

Merger Effective Time

At the effective
time of the Merger (the “Effective Time”), (a) each share of Longevity Common Stock (including shares issued in connection
with the Target Acquisitions and the conversion of certain Longevity indebtedness) outstanding immediately prior to the Merger Effective
Time (other than dissenting shares) will be converted into the right to receive a number of shares of FutureTech Common Stock equal to:
(i) the aggregate Merger Consideration divided by (ii) the number of outstanding shares of Longevity Common Stock (including each share
of Longevity Common Stock to be issued in connection with the Target Acquisitions and upon conversion of the Longevity indebtedness);
and (b) each outstanding Longevity vested option to purchase Longevity Common Stock shall be converted into a FutureTech option to acquire
the number of shares of FutureTech Common Stock calculated in accordance with the Merger Agreement; and (b) each share of FutureTech Common
Stock issued and outstanding immediately prior to the Merger Effective Time with respect to which a FutureTech stockholder